Wegovy weight‑loss pill now available for private purchase in UK pharmacies

A once‑daily oral weight‑loss medication produced by Novo Nordisk, the pharmaceutical company behind the injectable Wegovy (semaglutide), has become available for private purchase in pharmacies across the United Kingdom. The drug, marketed under the name Rybelsus, contains the same active ingredient as Wegovy but is formulated for oral administration, offering an alternative to the weekly injection for patients seeking medically supervised weight management.

The product is being sold through private channels rather than the National Health Service, meaning patients must pay the full retail price, which varies by pharmacy but is generally higher than the cost of the injectable version under NHS schemes. Novo Nordisk has highlighted the pill’s efficacy in clinical trials, noting comparable weight‑loss outcomes to the injection when taken consistently. Health professionals are required to prescribe the medication, and pharmacists are now stocking it alongside other prescription-only treatments. The introduction of the oral formulation expands access for individuals preferring a non‑injectable option, while also reflecting the growing market for pharmacological obesity therapies in the UK.